QuantLogix ← ELV scorecard
📅 ELV Earnings Preview
Elevance Health, Inc.
Next report (est.)
01/20/2027
Countdown
84 days
EPS growth YoY
+17.9%
Revenue growth YoY
+1.4%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
10/21/2026 ±2.2% -1.4% over-priced
07/15/2026 ±2.6% -8.5% under-priced
04/22/2026 ±3.0% +0.0% over-priced
02/06/2026 ±3.3% +2.0% over-priced
10/21/2025 ±1.9% -1.2% over-priced
07/17/2025 ±2.4% -12.2% under-priced
04/22/2025 ±4.7% +2.3% over-priced
02/20/2025 ±2.7% -0.3% over-priced
Across these reports, options implied an average ±2.8% move vs an actual average of 3.5% — the stock stayed inside the implied band 75% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q3 FY2026 $6.27 $51.4B $1.4B
Q2 FY2026 $6.71 $50.5B $1.5B
Q1 FY2026 $8.00 $50.2B $1.8B
Q4 FY2025 — $49.7B $547M
Analyst posture
Buy / Strong Buy
19
Hold
9
Sell
0
Stable: +0 net change 30d
Live 5-factor engine read: Buy · 79/100 Full scorecard →
Get alerted before every ELV report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on ELV before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Elevance Health, Inc. (ELV) reports in 84 days, with the next report estimated for 01/20/2027. Across the last 8 reports, options priced an average ±2.8% earnings move while the stock actually moved 3.5% on average — the market has systematically over-priced ELV's earnings risk. Fundamentals into the print: EPS up 17.9% year-over-year, revenue up 1.4%. QuantLogix's live 5-factor engine currently reads ELV as a buy at 79/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →